Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Marieke G G Sturkenboom"'
Autor:
Dissou Affolabi, Leen Rigouts, Tom Decroo, Armand Van Deun, Claude Muvunyi, Marieke G G Sturkenboom, Corinne S Merle, Jihad Snobre, Joel Gasana, Jean Claude Semuto Ngabonziza, Isabel Cuella-Martin, Bart Karl Jacobs, Emeline de Viron, Natacha Herssens, Jean Baptiste Ntihumby, Annualithe Klibazayre, Clement Ndayishimiye, Patrick Migambi, Bouke C de Jong, Yves Mucyo
Publikováno v:
BMJ Open, Vol 14, Iss 7 (2024)
Introduction An effective rifampicin-resistant tuberculosis (RR-TB) treatment regimen should include prevention of resistance amplification. While bedaquiline (BDQ) has been recommended in all-oral RR-TB treatment regimen since 2019, resistance is ri
Externí odkaz:
https://doaj.org/article/b77d6f49c11d449db051a9b561d26c1e
Autor:
Liesbeth F Mieras, Anna T Taal, Wim H van Brakel, Emmanuelle Cambau, Paul R Saunderson, W Cairns S Smith, Cita Rosita S Prakoeswa, Linda Astari, David M Scollard, Dejair Caitano do Nascimento, Jacques Grosset, Hemanta K Kar, Shinzo Izumi, Laura Gillini, Marcos C L Virmond, Marieke G G Sturkenboom
Publikováno v:
BMC Infectious Diseases, Vol 18, Iss 1, Pp 1-8 (2018)
Abstract The ongoing transmission of Mycobacterium (M.) leprae reflected in a very slow decline in leprosy incidence, forces us to be innovative and conduct cutting-edge research. Single dose rifampicin (SDR) as post-exposure prophylaxis (PEP) for co
Externí odkaz:
https://doaj.org/article/dcd880930d4c4ebf981b570331abf17d
Autor:
Laurynas Mockeliunas, Lina Keutzer, Marieke G. G. Sturkenboom, Mathieu S. Bolhuis, Lotte M. G. Hulskotte, Onno W. Akkerman, Ulrika S. H. Simonsson
Publikováno v:
Pharmaceutics, Vol 14, Iss 4, p 753 (2022)
Linezolid is an efficacious medication for the treatment of drug-resistant tuberculosis but has been associated with serious safety issues that can result in treatment interruption. The objectives of this study were thus to build a population pharmac
Externí odkaz:
https://doaj.org/article/610cde62416941eb9c0f796f9ffdb1e0
Autor:
Prakruti Rao, Anne-Grete Märtson, Stellah G. Mpagama, Kenneth C. Byashalira, Marieke G G Sturkenboom, Hannah Yejin Kim, Scott K. Heysell, Jan-Willem C. Alffenaar
Publikováno v:
Therapeutic Drug Monitoring, 44(1), 3-10. LIPPINCOTT WILLIAMS & WILKINS
BACKGROUND: Therapeutic drug monitoring (TDM) supports personalized treatment. For successful implementation, TDM must have a turnaround time suited to the clinical needs of patients and their health care settings. Here, the authors share their views
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ba85159190c293b496289f8cc587d66
https://doi.org/10.1097/FTD.0000000000000936
https://doi.org/10.1097/FTD.0000000000000936
Autor:
Samiksha Ghimire, Gladys Molinas, Arturo Battaglia, Nilza Martinez, Luis Gómez Paciello, Sarita Aguirre, Jan-Willem C. Alffenaar, Marieke G. G. Sturkenboom, Cecile Magis-Escurra
Publikováno v:
Pharmaceutics, 15, 4
Pharmaceutics, 15
Pharmaceutics; Volume 15; Issue 4; Pages: 1089
Pharmaceutics, 15
Pharmaceutics; Volume 15; Issue 4; Pages: 1089
Contains fulltext : 292330.pdf (Publisher’s version ) (Open Access) The aim of this study was to evaluate the difference in drug exposure of rifampicin in native versus non-native Paraguayan populations using dried blood spots (DBS) samples collect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10caccc88df583eefb3d761d66b6dfd1
https://hdl.handle.net/2066/292330
https://hdl.handle.net/2066/292330
Autor:
Daan J Touw, Marjolein Knoester, Anne-Grete Märtson, Angela E. Edwina, Marieke G G Sturkenboom, Jan-Willem C. Alffenaar, Hannah Yejin Kim
Publikováno v:
Therapeutic Drug Monitoring
Ther Drug Monit. 2021 Sep 30. doi: 10.1097/FTD.0000000000000925.
Ther Drug Monit. 2021 Sep 30. doi: 10.1097/FTD.0000000000000925.
BACKGROUND: Ganciclovir is the mainstay of therapy for the prophylaxis and treatment of Cytomegalovirus. However, therapy with this antiviral agent is hindered by side effects such as myelosuppression, which often leads to therapy cessation. Underdos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f15eafa9ef37a14c3de013662aad1f9
http://europepmc.org/articles/PMC8746890
http://europepmc.org/articles/PMC8746890
Autor:
Reihaneh Abolhassani-Chimeh, Onno W. Akkerman, Antonia M. I. Saktiawati, Nieko C. Punt, Mathieu S. Bolhuis, Yanri W. Subronto, null Sumardi, Tjip S. van der Werf, Jos G. W. Kosterink, Jan-Willem C. Alffenaar, Marieke G. G. Sturkenboom
Publikováno v:
Antimicrobial Agents and Chemotherapy, 66(7). AMER SOC MICROBIOLOGY
Antimicrob Agents Chemother
Antimicrob Agents Chemother
Pyrazinamide is one of the first-line antituberculosis drugs. The efficacy of pyrazinamide is associated with the ratio of 24-h area under the concentration–time curve (AUC(24)) to MIC. The objective of this study was to develop and validate a limi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1126546cd7b6e5cf72651f668cf3980
https://research.rug.nl/en/publications/1c4601e3-d753-4844-9dc2-9bb3ae8df6f7
https://research.rug.nl/en/publications/1c4601e3-d753-4844-9dc2-9bb3ae8df6f7
Autor:
Shashikant Srivastava, Anne-Grete Märtson, Jin-Gun Cho, Scott K. Heysell, Anthony Byrne, Asad E. Patanwala, Charles A. Peloquin, Hannah Y Kim, Marieke G G Sturkenboom, Simon Tiberi, Indy Sandaradura, Vitali Sintchencko, Jan-Willem C. Alffenaar, Gina Burch, Deborah Marriott
Publikováno v:
JO -Clinical Pharmacokinetics
Clinical Pharmacokinetics
Clinical Pharmacokinetics
Nontuberculous mycobacteria can cause minimally symptomatic self-limiting infections to progressive and life-threatening disease of multiple organs. Several factors such as increased testing and prevalence have made this an emerging infectious diseas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f82d14fedb5ab09916c2a1ae9cde7a72
https://doi.org/10.1007/s40262-021-01000-6
https://doi.org/10.1007/s40262-021-01000-6
Autor:
Kelly E. Dooley, Derek J. Sloan, Jan-Willem C. Alffenaar, Charles A. Peloquin, Rob E. Aarnoutse, Simone H J van den Elsen, Anne-Grete Märtson, Marieke G G Sturkenboom, Paolo Denti, Elin M. Svensson
Publikováno v:
Clinical Pharmacokinetics, 60, 6, pp. 685-710
Clinical Pharmacokinetics
Clinical Pharmacokinetics, 60, 685-710
Clinical Pharmacokinetics
Clinical Pharmacokinetics, 60, 685-710
Contains fulltext : 235795.pdf (Publisher’s version ) (Open Access) Tuberculosis (TB) is still the number one cause of death due to an infectious disease. Pharmacokinetics and pharmacodynamics of anti-TB drugs are key in the optimization of TB trea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1abb4ed666fda7be580bb31f5fe0b68
https://doi.org/10.1007/s40262-021-00997-0
https://doi.org/10.1007/s40262-021-00997-0
Autor:
Tjip S. van der Werf, Dick van Soolingen, Marieke G G Sturkenboom, Onno W. Akkerman, Richard M. Anthony, Wiel C M de Lange, Mathieu S. Bolhuis, Vanessa B Vogensen, Huib A. M. Kerstjens, Jan-Willem C. Alffenaar
Publikováno v:
Antimicrobial Agents and Chemotherapy, 66(2):e01829-21. AMER SOC MICROBIOLOGY
Antimicrob Agents Chemother
Antimicrob Agents Chemother
Moxifloxacin is an attractive drug for the treatment of isoniazid-resistant rifampicin-susceptible tuberculosis (TB) or drug-susceptible TB complicated by isoniazid intolerance. However, co-administration with rifampicin decreases moxifloxacin exposu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15a9f9ff8a8cc9d29e04b52704049c4b
https://research.rug.nl/en/publications/19364a90-b913-4be9-a073-401e4b3a043b
https://research.rug.nl/en/publications/19364a90-b913-4be9-a073-401e4b3a043b